Journal article
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
M West, A Kirby, RA Stewart, S Blankenberg, D Sullivan, HD White, D Hunt, I Marschner, E Janus, L Kritharides, GF Watts, J Simes, AM Tonkin
Journal of the American Heart Association | Published : 2022
Abstract
BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Ki..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The LIPID study was supported by a research grant from Bristol--Myers Squibb Pty Ltd and conducted under the auspices of the National Heart Foundation of Australia. Biomarker studies were funded by a project grant from the National Health and Medical Research Council of Australia (1037786).